% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koerber:141400,
      author       = {S. A. Koerber$^*$ and L. Will and C. Kratochwil$^*$ and M.
                      F. Haefner$^*$ and H. Rathke and C. Kremer and J. Merkle and
                      K. Herfarth$^*$ and K. Kopka$^*$ and P. L. Choyke and T.
                      Holland-Letz$^*$ and U. Haberkorn$^*$ and J. Debus$^*$ and
                      F. Giesel$^*$},
      title        = {68{G}a-{PSMA}-11 {PET}/{CT} in {P}rimary and {R}ecurrent
                      {P}rostate {C}arcinoma: {I}mplications for
                      {R}adiotherapeutic {M}anagement in 121 {P}atients.},
      journal      = {Journal of nuclear medicine},
      volume       = {60},
      number       = {2},
      issn         = {2159-662X},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2018-01906},
      pages        = {234-240},
      year         = {2019},
      note         = {vol. 60 no. 2 234-240},
      abstract     = {The present study analyzed the impact of Gallium-68
                      (68Ga)-labeled prostate-specific membrane antigen-HBED-CC
                      (68Ga-PSMA-11) positron-emission tomography (PET)/computed
                      tomography (CT) on radiotherapeutic management in a large
                      cohort of men with primary or recurrent disease. Methods:
                      This study investigated 121 men with carcinoma of the
                      prostate who underwent 68Ga-PSMA-11 PET/CT as well as
                      conventional imaging. 50 patients were treatment naive, 11
                      had persistent prostate-specific antigen (PSA) soon after
                      surgery and 60 presented with recurrent PSA following
                      definitive therapy. Changes in TNM classification of
                      malignant tumors (TNM) stage and radiotherapeutic management
                      after 68Ga-PSMA-11 imaging were compared to results achieved
                      with conventional imaging. Results: In total, a change in
                      TNM stage and radiotherapeutic management was observed for
                      49 patients $(40.5\%)$ and 62 patients $(51.2\%),$
                      respectively. In treatment naïve patients, a change in TNM
                      stage and radiotheraeutic plan occurred in $26.0\%$ and
                      $44.0\%$ of the cohort respectively. For patients with PSA
                      persistence or recurrence, TNM and radiotherapeutic
                      management changed in $50.7\%$ and $56.3\%$ respectively.
                      Conclusion:68Ga-PSMA-11 PET/CT may shortly become an
                      indispensable tool for detecting prostate cancer lesions in
                      treatment-naïve patients as well as in men with recurrent
                      disease or persistent PSA and seems to be very helpful in
                      personalizing radiotherapeutic management to the individual
                      patients' distribution of disease.},
      cin          = {E050 / E060 / E030 / L101 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)E060-20160331 /
                      I:(DE-He78)E030-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29976697},
      doi          = {10.2967/jnumed.118.211086},
      url          = {https://inrepo02.dkfz.de/record/141400},
}